Indivior price target raised to $22 from $16 at Northland

Northland analyst Carl Byrnes raised the firm’s price target on Indivior (INDV) to $22 from $16 and keeps an Outperform rating on the shares. Sublocade remains early in its penetration of “a large and underdiagnosed” opioid use disorder market, says the analyst, who views the treatment as well positioned to benefit from rising adoption of long-acting injectables in the buprenorphine-based medication-assisted treatment therapeutic category.